Abstract
Pancreatitis is increasingly recognized as not merely a local inflammation of the pancreas but also a disease with high frequency of systemic sequelae. Current understanding of the cellular mechanisms that trigger it and affect the development of sequelae are limited. Genetically engineered mouse models can be a useful tool to study the pathophysiology of pancreatitis. This article gives an overview of the genetically engineered mouse models that spontaneously develop pancreatitis and discusses those that most closely replicate different pancreatitis hallmarks observed in humans.
Highlights
Standardization for management of acute significant overall progress has development of metabolic disorders, such as exocrine been made during the last few decades (evidenced by a pancrDeeadtiiccatiendstuofPfiacuiel Pnlcayceh(EoPldIe)r, post-pancreatitis diabetes reduction in mortality rates), the improved outcomes mellitus (PPDM), and ectopic fat accumulation in the have not been due to any treatments based on specific pancreas [3,4,5,6]
Depending on the administration strategy employed this can resemble many of the common characteristics of human pancreatitis, including aberrant zymogen activation in the acinar cell, impaired exocrine pancreatic secretion, inflammation, morphological abnormalities, fibrosis and trans-differentiation of acini [13, 14]
An alternative approach that may be more specific to the underlying pathophysiology causing pancreatitis is the adoption of genetic mouse models
Summary
Journal xyz 2017; 1 (2): 122–135 genetically engineered mouse models (GEMM) that may be used to study the pancreatitis phenotype, with particular. AbstrTachte: PFairnsctreDateitcisadisein(1cr9e6as4in-1g9ly7r2ec)ognized as not focus on those that show hallmarks of the humans. MerelRyeaseloacracl hinAflarmticmlaetion of the pancreas and a disease with high frequency of systemic sequelae. 25, 2013; published on-linmeiJludly, 1m2,o2d0e14rate, severe, and critical) is useful for the clinical assessment of severity in individual patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
